235 related articles for article (PubMed ID: 11773186)
21. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
22. [STI571: the resistance organizes!].
Jeanteur P
Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
[No Abstract] [Full Text] [Related]
23. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.
Gorre ME; Sawyers CL
Curr Opin Hematol; 2002 Jul; 9(4):303-7. PubMed ID: 12042704
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
25. Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Mughal TI; Goldman JM
Front Biosci; 2006 Jan; 11():209-20. PubMed ID: 16146726
[TBL] [Abstract][Full Text] [Related]
26. STI571: a gene product-targeted therapy for leukemia.
Mauro MJ; Druker BJ
Curr Oncol Rep; 2001 May; 3(3):223-7. PubMed ID: 11296132
[TBL] [Abstract][Full Text] [Related]
27. Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?
Malhotra KP; Sharma CB; Jain J; Grover RK
J Postgrad Med; 2010; 56(3):221-2. PubMed ID: 20739774
[No Abstract] [Full Text] [Related]
28. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
29. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
van der Kuip H; Moehring A; Wohlbold L; Miething C; Duyster J; Aulitzky WE
Leuk Res; 2004 Apr; 28(4):405-8. PubMed ID: 15109541
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.
Gambacorti-Passerini CB; Gunby RH; Piazza R; Galietta A; Rostagno R; Scapozza L
Lancet Oncol; 2003 Feb; 4(2):75-85. PubMed ID: 12573349
[TBL] [Abstract][Full Text] [Related]
31. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
von Bubnoff N; Peschel C; Duyster J
Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
[TBL] [Abstract][Full Text] [Related]
32. Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model.
Chaturvedi A; Battmer K; Schaefer D; Ganser A; Eder M; Scherr M
Oligonucleotides; 2007; 17(1):22-34. PubMed ID: 17461760
[TBL] [Abstract][Full Text] [Related]
33. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
34. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
[TBL] [Abstract][Full Text] [Related]
35. STI571: targeting BCR-ABL as therapy for CML.
Mauro MJ; Druker BJ
Oncologist; 2001; 6(3):233-8. PubMed ID: 11423669
[TBL] [Abstract][Full Text] [Related]
36. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
37. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
Mazzacurati L; Pattacini L; Brusa G; Mancini M; Benvenuti M; Barbieri E; Martinelli G; Baccarani M; Greenberger JS; Santucci MA
Hematol J; 2004; 5(2):168-77. PubMed ID: 15048068
[TBL] [Abstract][Full Text] [Related]
38. [Resistance mechanism of ST1571 and its prevention research--review].
Zhou X; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Oct; 12(5):713-7. PubMed ID: 15498142
[TBL] [Abstract][Full Text] [Related]
39. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
Bazeos A; Marin D; Reid AG; Gerrard G; Milojkovic D; May PC; de Lavallade H; Garland P; Rezvani K; Apperley JF; Goldman JM; Foroni L; Khorashad JS
Leukemia; 2010 Jun; 24(6):1243-5. PubMed ID: 20445576
[No Abstract] [Full Text] [Related]
40. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Kurzrock R; Kantarjian HM; Druker BJ; Talpaz M
Ann Intern Med; 2003 May; 138(10):819-30. PubMed ID: 12755554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]